Impact of IQOS Patent Invalidation on Chinese E-Cigarette Industry

Jan.09.2023
Impact of IQOS Patent Invalidation on Chinese E-Cigarette Industry
PMI-BAT patent battle over IQOS temporarily ended, gives Chinese e-cigarette companies more opportunities. Learn from the experience on Jan 12.

In December, the patent war between Philip Morris International (PMI) and British American Tobacco (BAT) temporarily concluded with the invalidation of the IQOS core patent in the UK. In the game between the two tobacco giants in the European market, PMI's four heat-not-burn (HNB) patents were ruled invalid, greatly reducing the risk of HNB products entering the European market and presenting more opportunities for electronic cigarette manufacturers in Europe. So, how does the invalidation of the IQOS core patent affect Chinese electronic cigarette companies? How should Chinese electronic cigarette companies respond to patent issues when going global? What experience can Chinese electronic cigarette companies gain from this patent war?


On January 12th at 2 pm, 2FIRSTS held a seminar on the PMI-HNB Resistance Heater Patent Lawsuit. The event featured keynote speakers from the Beijing Zhong Lun Wende (Kunming) law firm and tobacco industry expert lawyer Tang Shunliang, who provided a comprehensive overview of the patent disputes between two major tobacco companies. They also explored the profound implications for Chinese e-cigarette manufacturers following the breakthrough of the HNB resistance heater patent barrier.


Live broadcast explanation


Title: Seminar on Patent Litigation Case of "PMI-HNB Resistance Heater


Date and Time: January 12th, from 2:00 PM to 3:00 PM.


Speaker: Lawyer Tang Shunliang


Content arrangement:


Key Patent Litigation Analysis for BAT and PMI from 2020 to 2022.


2. Analyzing the Legal Documents to Understand the Battle Strategies between Two Tobacco Giants.


3. In-depth analysis of the core patented technology scheme of the resistance heating element.


What risks and opportunities do export-oriented e-cigarette companies face?


Summarizing the experience in handling foreign patents from PMI patent case.


After the lecture, there will be a dedicated session for discussion and questions, and we encourage active participation and communication.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Reports Fiscal Q3 2026 Revenue of $18.7 Million and Net Loss of $9.5 Million
Ispire Technology reported financial results on May 7, 2026, for the third quarter of fiscal 2026, covering the three months ended March 31, 2026. Revenue was $18.7 million, compared with $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior quarter. Gross profit was $2.0 million, with gross margin of 10.7%. Net loss was $9.5 million, or $0.17 per share. The company said it held $18.0 million in cash as of March 31, 2026, up $468,000 sequentially.
May.08 by 2FIRSTS.ai
Alan Zhao: What the Rise of Nicotine Pouches Means for Tobacco Retailers
Alan Zhao: What the Rise of Nicotine Pouches Means for Tobacco Retailers
Alan Zhao argues that nicotine pouches are no longer a niche alternative, but a force quietly reshaping the future of tobacco retail. For distributors and retailers, the real risk is not missing a trend—it is moving too late, after regulation tightens, shelf space hardens and the market begins to choose its winners.
Mar.31 by Alan Zhao | 2Firsts Perspectives
Reuters Exclusive: FDA’s Fast-Track Review of Nicotine Pouches Slows Over Youth and New-User Concerns
Reuters Exclusive: FDA’s Fast-Track Review of Nicotine Pouches Slows Over Youth and New-User Concerns
Reuters reported on April 1 that several popular nicotine pouch products still have not been cleared for sale in the United States despite a fast-track review pilot run by the U.S. Food and Drug Administration. Three sources said FDA reviewers have taken a cautious approach because of potential risks to youth and other non-tobacco users, including the possibility of driving nicotine addiction among adults who do not already smoke.
Apr.02 by 2FIRSTS.ai
Alberta Seeks to Add New Vape Restrictions on Top of Existing Tobacco Framework
Alberta Seeks to Add New Vape Restrictions on Top of Existing Tobacco Framework
A new Alberta bill aimed at reducing vaping rates, especially among young people, is moving into the legislative process. Bill 208, the Vaping Reduction Act, was introduced by United Conservative Party MLA Chelsae Petrovic and appears to build on the province’s existing Tobacco, Smoking and Vaping Reduction Act. Early reporting suggests the bill could focus on disposable vapes and impose further limits on youth access to vaping products.
Apr.15 by 2FIRSTS.ai
Bloomberg: Zyn’s Dry-Mouth Problem Threatens Its Hold on Nicotine Pouch Market
Bloomberg: Zyn’s Dry-Mouth Problem Threatens Its Hold on Nicotine Pouch Market
According to Bloomberg, Philip Morris International’s Zyn is facing growing competition in the U.S. nicotine pouch market as consumers shift toward moister alternatives such as British American Tobacco’s Velo Plus.
BATPMI
May.22
FDA Expands ENDS Market Access With First Authorization of Non-Tobacco and Non-Menthol Products
FDA Expands ENDS Market Access With First Authorization of Non-Tobacco and Non-Menthol Products
The U.S. Food and Drug Administration (FDA) announced on May 5, 2026 that it authorized the marketing of four Glas electronic nicotine delivery system (ENDS) products through the premarket tobacco product application (PMTA) pathway. The authorized products are Classic Menthol, Fresh Menthol, Gold and Sapphire pods, each containing 50mg/ml, or 5%, tobacco-derived nicotine.
May.06 by 2FIRSTS.ai